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ABSTRACT 
Objective: The present method was proposed to develop a simple, sensitive, rapid, accurate and stability-indicating reverse phase-high performance 
liquid chromatographic (RP-HPLC) method for the simultaneous estimation of metformin and teneligliptin in pure and pharmaceutical formulations.  
Methods: The chromatographic separation was done on Discovery [250 mm X 4.6 mm: 5 μm is particle size] using a mobile phase composed of 
0.1% orthophosphoric acid buffer: acetonitrile [65:35, v/v], the flow rate is 1 ml/min and the detection was carried out with a photodiode array 
(PDA) at 260 nm. 
Results: The retention time of metformin and teneligliptin were found to be 2.517 min and 3.687 min, respectively. Stability indicating studies were 
conducted under the guidelines of an international conference on harmonization [ICH] Q1A R2 and the developed method was validated as per the 
guidelines of ICH Q2 R1. The linearity was found in the range of concentration of 125-750 μg/ml and 5-30 μg/ml for metformin and teneligliptin. 
The lower limit of detection (LOD) and lower limit of quantification (LOQ) was found to be 0.02μg/ml and 0.07 μg/ml for metformin and 0.19 μg/ml 
and 0.56 μg/ml for teneligliptin, respectively. 
Conclusion: A novel stability-indicating reverse phase liquid chromatographic method developed for the simultaneous estimation of metformin and 
teneligliptin. The proposed method was adopted for the routine estimation of metformin and teneligliptin in bulk and pharmaceutical dosage forms.  
Keywords: Method validation, Estimation, Stability indicating, RP-HPLC, Metformin, Teneligliptin 




Metformin (fig. 1) category is biguanide and chemically called as N, 
N-dimethyl imidodicarbonimidic diamide hydrochloride. It is used 
for the treatment of type 2 diabetes, and limited use to prevent the 
cardiovascular disease and cancer complications of diabetes [1]. 
Teneligliptin (fig. 2) is potent, competitive and long-acting DPP-1V 
inhibitor and chemically called as {(2S, 4S)-4-[4-(3-methyl-1-phenyl-
1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl} (1,3-thiazolidin-3-yl) 
methanone. It is used for the treatment of type-2 diabetic mellitus [2]. 
Literature survey revealed that very few analytical method had been 
reported for the estimation of metformin and teneligliptin by using 
ultraviolet spectroscopy [3-6], HPLC [7-10], ultra performance liquid 
chromatography (UPLC) [11-12], and liquid chromatography-mass 
spectroscopy (LC-MS) [13-14] by individually or simultaneously 
with other drugs. From the literature survey, it confirms that there is 
no method has been reported for the stability indicating a 
simultaneous estimation of metformin and teneligliptin in pure and 
pharmaceutical dosage form by using RP-HPLC.  
The present method has so many advantages like simple standard 
preparation process, a large range of concentration with high 
sensitivity, low-cost solvent are used in mobile phase preparation 
and all parameters must be validated as per ICH guidelines [15-16]. 
Hence, the developed method was used for the simultaneous 
determination of metformin and teneligliptin in pure and 
pharmaceutical dosage forms. 
MATERIALS AND METHODS 
Instruments 
The system composed Waters HPLC 2695 equipped with quaternary 
pumps with PDA detector. The chromatographic separation was 
done on Discovery [250 mm X 4.6 mm, 5 μm particle size] column. 




Fig. 1: structure of metformin [17] 
 
 
Fig. 2: Structure of teneligliptin [17] 
  
Chemical solutions and reagents 
Metformin and Teneligliptin obtained from Spectrum Research 
Private limited, [Hyderabad, India]. Orthophosphoric acid purchased 
from Qualigens fine chemicals limited [Mumbai, India] and 
acetonitrile [HPLC grade] purchased from Merck chemicals private 
limited [Mumbai, India]. 
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Preparation of standard and working standard solutions  
The powder of 50 mg of metformin and 2 mg of teneligliptin were 
weighed and transferred into a 100 ml of calibrated volumetric 
flasks, 70 ml of diluent was added and sonicated for 25 min and 
makeup to the final volume with diluents. 1 ml was pipetted out 
from above stock solution and transferred into 10 ml volumetric 
flask and made up to 10 ml with diluent.  
Preparation of mobile phase buffer 
The buffer solution was prepared by dissolving 1 ml orthophosphoric 
acid in 1000 ml of water.  
Mobile phase composition 
Method development for the simultaneous estimation of metformin and 
teneligliptin was begun with a different combination of solvents with 
different ratios like [35:65, 45:55, and 50:50]. Although, finally a 
combination of 0.1% orthophosphoric acid buffer: acetonitrile [65:35, 
v/v] has appeared good resolution for metformin and teneligliptin. 
Sample preparation 
20 tablets were weighed and calculate the average weight of each 
tablet then the weight equivalent to 1 tablet was transferred into a 
100 ml volumetric flask, 70 ml of diluent added and sonicated for 25 
min, further the volume made up with diluent and filtered. From the 
filtered solution 1 ml was pipetted out into a 10 ml volumetric flask 
and made up to 10 ml with diluent.  
Chromatographic conditions  
The method development for separation of metformin and teneligliptin 
by using different solvents, finally the separation was achieved with a 
mobile phase 0.1% orthophosphoric acid buffer: acetonitrile [65:35, 
v/v], pumped at a flow rate is 1 ml/min. The eluent detection was 
carried out at 260 nm, by observing of PDA detector. The mobile phase 
was vacuum filtered through a 0.45 μm membrane filter. 
Method validation 
The developed method was validated according to 2005 ICH 
guidelines for validation of analytical procedures. Validation 
parameters according to the guideline of ICH Q2R1 include system 
suitability, linearity, precision, LOD, LOQ and accuracy, robustness 
under the guideline. 
System suitability 
Verifying the system suitability parameters like theoretical plate count, 
tailing factor, percentage relative standard deviation of the peak and 
retention time, resolution, system suitability tests were carried out to 
ensure optimized chromatographic conditions are suitable for analysis 
of metformin and teneligliptin. Mixed standard solutions containing 
metformin (500µg/ml) and teneligliptin (20µg/ml) were prepared. Six 
replicate injections of the above standard solutions were injected into 
the column. System suitability parameters of typical chromatograms 
were analyzed using the proposed HPLC method. 
Linearity, range and calibration curve  
The range of linearity was evaluated between 125-750 μg/ml for 
metformin and 5-30 μg/ml and for teneligliptin at an injection 
volume of 10 µl. The calibration curve was a plot between 
concentration against corresponding peak area and linearity was 
estimated by the least square method. 
Precision 
The precision of the developed method was carried out for same 
concentration level in terms of repeatability and intermediate 
precision. Six determinations were established, both intra-day and 
inter-day precision were conveyed in terms of percent relative 
standard deviation [% RSD].  
LOD and LOQ 
Determination value of the limit of detection and quantification by 
using the following formulas:  
Limit of detection= 3.3 α/S 
Limit of quantitation= 10 α/S 
Where α is the standard deviation of the y-intercept and S is the 
slope from linearity plot 
Accuracy 
The accuracy was estimated by using the standard addition method 
at 50 %, 100 %, and 150 % levels. The percentage recovery and 
percentage relative standard deviations [%RSD] were taken into 
consideration for examine the accuracy. 
Specificity 
Specificity was established by comparing 3D plots of pure drug and 
drug product with blank and placebo, and by peak purity test, which 
shown that analyte chromatographic peak is not determinable to 
more than two components and no impurities are available by peak 
purity index. The data was given in fig. 9 and 10. 
Robustness 
Robustness was estimated by making slight and deliberate changes 
in chromatographic conditions like flow rate, mobile phase. The data 
was summarized in table 8 and 9. 
Stability indicating studies 
Acid hydrolysis 
1 ml stock solution of metformin and teneligliptin, 1 ml of 2N 
hydrochloric acid was added and refluxed for 30 min at 60 °C. The 
solution was diluted to obtain 500 μg/ml for metformin and 20 
μg/ml for teneligliptin. 10 μl solutions were injected into the system 
and the chromatograms were recorded to assess the stability of the 
sample. 
Base hydrolysis 
1 ml stock solution of metformin and teneligliptin, 1 ml of 2N 
sodium hydroxide was added and refluxed for 30 min at 60 °C. The 
solution was diluted to obtain 500 μg/ml for metformin and 20 
μg/ml for teneligliptin. 10 μl solutions were injected into the system 
and the chromatograms were recorded to assess the stability of the 
sample. 
Peroxide hydrolysis  
1 ml stock solution of metformin and teneligliptin, 1 ml of 20% 
hydrogen peroxide was added and refluxed for 30 min at 60 °C. The 
solution was diluted to obtain 500 μg/ml for metformin and 20 
μg/ml for teneligliptin. 10 μl solutions were injected into the system 
and the chromatograms were recorded to assess the stability of the 
sample. 
Thermal hydrolysis 
1 ml stock solution of metformin and teneligliptin, placed in oven at 
105 °C for 6 h. The solution was diluted to obtain 500 μg/ml for 
metformin and 20 μg/ml for teneligliptin. 10 μl solutions were 
injected into the system and the chromatograms were recorded to 
assess the stability of the sample. 
Photo hydrolysis 
Exposing the 5000 µg/ml for metformin and 200 µg/ml for 
teneligliptin solution to UV Light by keeping the beaker in UV 
chamber for 7days or 200 Watt-hours/m2 in photostability chamber. 
The resultant solution was diluted to obtain 500µg/ml for 
metformin and 20 µg/ml for teneligliptin solutions. 10 µl were 
injected into the system, and the chromatograms were recorded to 
assess the stability of the sample. 
Neutral hydrolysis 
Refluxing the drug solutions in water for 6 h. at a temperature at 60 °C. 
The solution was diluted to obtain 500 μg/ml for metformin and 20 
μg/ml for teneligliptin. 10 μl solutions were injected into the system and 
the chromatograms were recorded to assess the stability of the sample. 
Swetha et al. 




Optimization of chromatographic conditions 
The analytical conditions were selected, keeping in mind the 
chemical nature of metformin and teneligliptin. The development 
trails were taken using different conditions. The column selection 
has been done on the basis of back pressure, peak shape and 
theoretical plates. After evaluating all these factors, the 
chromatographic separation was carried out on Discovery column 
[250 mm X 4.6 mm; 5 μm is particle size] using a mobile phase 
consisting 0.1% orthophosphoric acid buffer: acetonitrile [65:35 
v/v], the flow rate 1 ml/min and the injection volume were 10 μl, the 
detection was carried out with PDA detector at 260 nm. The peak 
retention time of metformin and teneligliptin were found to be 2.517 
min and 3.687 min respectively. Hence this method was finalized as 
an optimized method for the simultaneous estimation of metformin 
and teneligliptin. The optimized chromatographic condition was 
shown in table 1 and the typical HPLC chromatogram of blank, 
standard and placebo, the sample were shown in fig. 3, 4 and 5, 6. 
 
Table 1: Optimized chromatographic condition for the estimation of metformin and teneligliptin 
Parameter Condition 
Mobile phase 0.1 % Ortho phosphoric acid buffer: acetonitrile [65:35 v/v] 
Diluent Water: acetonitrile 
Column Discovery (250 mm X 4.6 mm, 5μm is particle size) 
Detector PDA 
Column temperature 30 °C 
Detection wavelength 260 nm 
Injection volume 10 μl 
Flow rate 1 ml/min 
Run time 6 min 
 
 
Fig. 3: Typical HPLC chromatogram of blank 
 
 
Fig. 4: Typical HPLC chromatogram of standard 
 
 
Fig. 5: Typical chromatogram of placebo 
 
Fig. 6: Typical HPLC chromatogram of a sample 
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The developed method has produced a theoretical plate above 2000 
for metformin and teneligliptin with tailing factor less than 2. 
Similarly, the percent relative standard deviation [% RSD] of 
metformin and teneligliptin were less than 2, which ensure the 
suitability of the developed method. The results of the system 
suitability study were summarized in table 2. 
 
Table 2: System suitability of the developed method 
Parameters Metformin Teneligliptin Acceptance criteria 
Retention time(min) 2.517 3.687 ……. 
Theoretical plates 9788 6734 >2000 
Tailing factor 1.22 1.40 <2 
Asymmetry factor 1.68 1.75 >1<10 
Resolution 8.0 8.0 >2 
 
Linearity 
For linearity of six point’s calibration curve were obtained in 
concentration ranges from 125-750 μg/ml for metformin and 5-30 
μg/ml for teneligliptin. The response of the drug was found to be 
linear in the selected concentration range. The correlation 
coefficient for metformin and teneligliptin were 0.9993 and 
0.9991 respectively. The results of the linearity of metformin and 
teneligliptin were summarized in table 3 and 4 and the data was 




Fig. 7: Standard calibration curve of [A] metformin [B] teneligliptin 
 
Table 3: Linearity and range of Metformin (n=3) 
S. No. Concentration (μg/ml) Peak area (mean±SD) 
1 125 1092284±1850.1 
2 250 2040782±14336.2 
3 375 3006306±7370.4 
4 500 4217649±28145.6 
5 625 5222174±24778.4 
6 750 6198935±17844.1 
Slope  8295.3 
Y-intercept  434.4 
Correlation coefficient  0.9993 
n is number of determination, SD is standard deviation 
 
Table 4: Linearity and range of Teneligliptin (n=3) 
S. No. Concentration (μg/ml) Peak area (mean±SD) 
1 5 106601±606.5 
2 10 205080±880.5 
3 15 294146±5729.8 
4 20 380439±2798.5 
5 25 473114±5898.1 
6 30 569050±7931.1 
Slope  18682 
Y-intercept  9539.8 
Correlation coefficient  0.9991 
n is number of determination, SD is standard deviation 
 
 
Fig. 8: Overlay of precision chromatograms 
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Table 5: Intra-day and inter-day precision of the developed method for metformin (n=6) 
Drug Concentration 
(μg/ml) 
Intra-day precision  Inter-day precision 
mean±SD  %RSD mean±SD  %RSD 
Metformin 500 4248866±32475  0.8 4203360±12451.8  0.3 
n is number of determination, SD is standard deviation, RSD is relative standard deviation 
 
Table 6: Intra-day and inter-day precision of the developed method for teneligliptin (n=6) 
Drug Concentration 
(μg/ml) 
Intra-day precision  Inter-day precision 
mean±SD %RSD mean±SD  %RSD 
Teneligliptin 20 386861±2720  0.7 334998±1130.5  0.3 
n is number of determination, SD is standard deviation, RSD is relative standard deviation 
 
Precision 
The developed method has shown percent relative standard 
deviation [% RSD] less than 2 for both intra-day and inter-day 
precision study, which ensures precision of the developed method. 
The results of the precision study were summarized in table 5 and 6, 
and the data was shown in fig. 8. 
Lower limit of detection (LOD) and lower limit of quantification 
(LOQ) 
LOD and LOQ were estimated from the standard deviation of the y-
intercepts and slope of the calibration curve of metformin and 
teneligliptin. The LOD and LOQ were found to be 0.02 and 0.07 
μg/ml for metformin and 0.19 and 0.56 μg/ml for teneligliptin. This 
showed that the developed method can detect and quantify at lower 
concentration was highly sensitive whereas other methods is less 
sensitive. 
Accuracy 
The percentage recovery of the spiked sample was within 99±2% 
which ensures the accuracy of the developed method. The results of 
recovery studies were summarized in table 7 and 8. 
Specificity 
Specificity was established by spiking diluent solution of tablet 
formulation excipients (placebo). The resultant chromatogram 
shown that no peaks at Rt of metformin 2.517 and teneligliptin 
3.687.
 
Table 7: Accuracy of the developed method for metformin (n=3) 










50 250 247.3±2.23 98.5±0.2  
98.8±0.68 100 500 493.1±3.61 98.62±0.7 
150 750 744.1±6.96 99.2±0.93 
n is number of determination, SD is standard deviation 
 
Table 8: Accuracy of the developed method for teneligliptin (n=3) 












50 10 9.91±0.03 99.11±0.36  
99.46±0.89 100 20 19.9±0.18 99.83±0.92 
150 30 29.8±0.4 99.43±1.34 
n is number of determination, SD is standard deviation 
 
Table 9: Robustness of developed method for metformin (n=6) 
Parameter Peak area (mean±SD) %RSD 
Flow rate plus (70:30 v/v) 3754398±13745.3 0.4 
Flow rate minus (60:40 v/v) 4601714±26047.6 0.6 
Mobile phase plus (1.1 ml) 3798055±14382.3 0.4 
Mobile phase minus (0.9 ml) 3776325±15684.8 0.4 
n is number of determination, SD is standard deviation, RSD is relative standard deviation 
 
Table 10: Robustness of the developed method for teneligliptin (n=6) 
Parameter Peak area (mean±SD) %RSD 
Flow rate plus (70:30 v/v) 325266±4911.8 1.5 
Flow rate minus (60:40 v/v) 366352±2611.8 0.7 
Mobile phase plus (1.1 ml) 306216±2145.2 0.7 
Mobile phase minus (0.9 ml) 346556±4557.2 1.3 
n is number of determination, SD is standard deviation, RSD is relative standard deviation 
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[A]      [B] 
Fig. 9: 3D plot of [A] Standard [B] Blank 
 
  
[A]      [B] 
Fig. 10: 3D plot of [A] Sample [B] Placebo 
 
Assay 
The assay was estimated by injecting prepared concentration of tablet 
formulation into HPLC. Assay result was calculated by comparing the 
peak area of tablet formulation with a peak area of standard solution. 
% assay of metformin and teneligliptin was found to be 99.47% and 
100.24% respectively. % assay for both drugs was found to be more 
than 99.4%. Hence the method was successfully applied for estimation 
of metformin and teneligliptin in bulk and pharmaceutical 
formulation. The results of assay data were summarized in table 11. 
 
Table 11: Assay data for formulation of metformin and teneligliptin (n=6) 
Formulation Labelled amount(mg) % Assay (mean±SD) % RSD 






n is number of determinations, SD is standard deviation, RSD is relative standard deviation 
 
Stability-indicating studies 
Stability indicating studies were carried under a condition of 
acid/base/neutral hydrolysis, oxidation, dry heat and photolysis. For 
each study, samples were prepared. The blank subjected to stress in the 
same manner for the drug solution, working standard solution of 
metformin and teneligliptin subjected to stress degradation. Dry heat 
and photolytic degradation were carried out in a solid state. The 
concentration of degrading reagent and time of exposure was optimized 
to degradation within the range of 10%. During optimization of 
degradation conditions, if the higher percentage of degradation was 
observed, milder conditions were used for the lesser duration of 
exposure.  
 
Degradation product peak at Rt of 1.583 
Fig. 11: Chromatogram of acid hydrolysis 
 
 
Degradation product peak at Rt of 1.727 
Fig. 12: Chromatogram of alkali hydrolysis 
 
 
Degradation product peak at Rt of 1.260 
Fig. 13: Chromatogram of peroxide hydrolysis 
 
Although percent assay reduced under all conditions; the separate peak 
for degradation product was observed only under acid, alkali and 
oxidative conditions showing in fig 11, 12 and 13. Summary of stress 
degradation results is given in table 12 and 13. 
 
Table 12: Stability-indicating data of metformin 
Degradation parameter Peak area of the sample Peak area of 
standard 
% Recovery % Degradation 
Acid degradation 4059092 4267272 95.03 4.97 
Alkali degradation 4155479 4267272 97.28 2.72 
Oxidative degradation 4191118 4267272 98.12 1.88 
Dry heat degradation 4248957 4267272 99.47 0.53 
Photo stability degradation 4247378 4267272 99.43 0.57 
Neutral degradation 4236053 4267272 99.17 0.83 
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Table 13: Stability-indicating data of teneligliptin 
Degradation parameter Peak area of sample Peak area of standard % Recovery % Degradation 
Acid degradation 366712 385565 95.02 4.98 
Alkali degradation 375116 385565 97.19 2.81 
Oxidative degradation 379152 385565 98.24 1.76 
Dry heat degradation 382367 365565 99.07 0.93 
Photo stability degradation 383633 385565 99.40 0.60 
Neutral degradation 382781 385565 99.18 0.82 
 
DISCUSSION 
Stability indicating RP-HPLC method is a simple, rapid, precise, 
accurate method for analyzing each component in the mixture. The 
previous study had reported that determination of metformin and 
teneligliptin by three differential spectrophotometric methods [6]. In this 
RP-HPLC method, we used PDA detector to prove the selectivity of the 
method. The method was validated according to ICH guidelines on 
validation of analytical procedures and stability testing of new drug 
substances and products. In order to develop an RP-HPLC method for 
estimation of metformin and teneligliptin, different buffer ratios at 
different flow rates were applied. As 0.1% orthophosphoric acid buffer: 
acetonitrile [65:35 v/v] as mobile phase and discovery C18 column 
stationary phase was selected. Separation of metformin at 2.517 min and 
teneligliptin at 3.687 min was detected by PDA detector. The previous 
study had reported that simultaneous estimation of metformin and 
teneligliptin with UV detector at different mobile phase and different 
column, separation of metformin and teneligliptin was detected at 3.317 
min and 4.783 min [10]. In the reported method, separation of 
metformin and teneligliptin was 1 min longer than this method and no 
stability indicating studies were reported. In this method, PDA detector 
able to identify metformin, teneligliptin and degradation products. 
Method was validated, the result of validation parameters had shown in 
compliance of ICH guidelines. The range of linearity had good correlation 
with concentration and peak area. The correlation coefficient for 
metformin and teneligliptin were 0.9993 and 0.9991 respectively, which 
indicates that at this concentration range both were highly linear. 
Present assay, the amount of both the drugs recovered was found to be 
98.78% for metformin and 99.46% for teneligliptin. Hence, the 
developed RP-HPLC stability indicating assay method was found to be 
appropriate for the analysis of drug in their pharmaceutical dosage form. 
Separation of degradation peak for degradation product was observed 
under acidic, alkaline hydrolysis and oxidation conditions at 1.583 min, 
1.727 min, 1.260 min respectively. Compared to the previous method, 
this method is stability indicating, selective, sensitive and separation was 
detected at the shorter run time.  
CONCLUSION 
The newly developed RP-HPLC method for simultaneous determination 
of metformin and teneligliptin in pure and in the pharmaceutical 
formulation was found to be simple, sensitive, rapid, precise and 
accurate. The proposed method was completely validated as per ICH 
guidelines. The method was proved to be superior to previous methods 
in terms of selectivity, sensitivity, and stability indicating studies. The 
method validation data are showing satisfactory results for all the 
method parameters tested. The stability-indicating nature of the 
proposed method was established by performing forced degradation, 
which provided degradation behavior of metformin and teneligliptin 
under various conditions and it was proved that stressed samples do not 
interfere with degradation products and excipients. Hence the developed 
RP-HPLC method is stability-indicating and can be used for routine 
analysis of production samples and also to check the stability of bulk 
samples of metformin and teneligliptin. 
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